U.S was Charles River Laboratories International’s largest region in fiscal 2025, bringing in $2.14B of $4.02B (53%).
| Geography | FY 2010 | FY 2012 | FY 2014 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| U.S | $2.34B | $2.35B | $2.24B | $2.14B | |||||||||
| Europe | $1.03B | $1.08B | $1.08B | $1.10B | |||||||||
| Canada | $398.98M | $487.31M | $482.09M | $501.03M | |||||||||
| Asia Pacific | $192.84M | $200.83M | $196.95M | $205.02M | |||||||||
| Japan | — | — | — | — | |||||||||
| Other Non-U.S | — | — | — | — | |||||||||
| Other | $9.96M | $16.85M | $52.82M | $64.87M | |||||||||
| Total | $3.98B | $4.13B | $4.05B | $4.02B |
Charles River Laboratories International brought in $4.02B from its five regions in fiscal 2025, the year ended December 27, 2025. That was down 0.9% from $4.05B in fiscal 2024. U.S was the largest at $2.14B (53.3%), ahead of Europe at $1.10B (27.5%) and Canada at $501.03M (12.5%). The other two regions brought in $269.89M combined.
Compared with fiscal 2024, Asia Pacific grew fastest, up 4.1% to $205.02M, while U.S fell the most, down 4.4% to $2.14B. From fiscal 2022 to 2025, combined revenue from these regions grew from $3.98B to $4.02B, a compound annual growth rate of 0.3%. U.S's share of the total fell from 58.9% to 53.3%.
Dsa was Charles River Laboratories International’s largest revenue line in fiscal 2025, bringing in $2.40B of $3.24B (74%).
| Timing of Transfer of Good or Service | FY 2010 | FY 2012 | FY 2014 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dsa | $2.44B | $2.61B | $2.45B | $2.40B | |||||||||
| Discovery & Safety Assessment | — | — | — | — | |||||||||
| Research Models & Services | — | — | — | — | |||||||||
| Preclinical Services | — | — | — | — | |||||||||
| Rms | $398.47M | $414.40M | $448.48M | $456.99M | |||||||||
| Manufacturing Support | — | — | — | — | |||||||||
| Manufacturing | $418.07M | $381.94M | $407.47M | $383.68M | |||||||||
| Other Manufacturing Support | — | — | — | — | |||||||||
| Emd | — | — | — | — | |||||||||
| Total | $3.26B | $3.41B | $3.30B | $3.24B |
Charles River Laboratories International brought in $3.24B from its three revenue lines in fiscal 2025, the year ended December 27, 2025. That is less than the $4.02B it reports by geography, so these revenue lines do not cover all of its revenue. Dsa was the largest at $2.40B (74.1%), ahead of Rms at $456.99M (14.1%) and Manufacturing at $383.68M (11.8%).
Compared with fiscal 2024, Rms grew fastest, up 1.9% to $456.99M, while Manufacturing fell the most, down 5.8% to $383.68M.
Service was Charles River Laboratories International’s largest product and service line in fiscal 2025, bringing in $3.25B of $4.02B (81%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Service | $3.22B | $3.44B | $3.30B | $3.25B | ||||||
| Cost Of Services Provided (Excluding Amortization Of Intangible Assets) | — | — | — | — | ||||||
| Product | $759.16M | $689.39M | $745.85M | $765.28M | ||||||
| Cost Of Products Sold (Excluding Amortization Of Intangible Assets) | — | — | — | — | ||||||
| Total | $3.98B | $4.13B | $4.05B | $4.02B |
Charles River Laboratories International brought in $4.02B from its two product and service lines in fiscal 2025, the year ended December 27, 2025. That was down 0.9% from $4.05B in fiscal 2024. Service was the largest at $3.25B (80.9%), ahead of Product at $765.28M (19.1%).
Compared with fiscal 2024, Product grew 2.6% to $765.28M, while Service fell 1.6% to $3.25B. From fiscal 2022 to 2025, combined revenue from these lines grew from $3.98B to $4.02B, a compound annual growth rate of 0.3%. Service's share held steady at about 80.9%.
Charles River Laboratories International (CRL) reports its revenue by geography, by timing of transfer of good or service and by product and service. In fiscal 2025, U.S was its largest region, bringing in $2.14B (53.3% of the total), followed by Europe at $1.10B (27.5%).
U.S was Charles River Laboratories International's largest region in fiscal 2025, bringing in $2.14B, or 53.3% of the $4.02B total across its five regions.
Dsa was Charles River Laboratories International's largest revenue line in fiscal 2025, bringing in $2.40B, or 74.1% of the $3.24B total across its three revenue lines.
Service was Charles River Laboratories International's largest product and service line in fiscal 2025, bringing in $3.25B, or 80.9% of the $4.02B total across its two product and service lines.
Among Charles River Laboratories International's regions that make up at least 2% of revenue, Asia Pacific grew fastest in fiscal 2025, up 4.1% from $196.95M to $205.02M.
Every figure comes from Charles River Laboratories International's annual financial filings, as reported. Each line keeps the name Charles River Laboratories International gives it, and years follow its fiscal calendar.
Charles River Laboratories International's revenue by geography goes back to fiscal 2010, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.